One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Achondroplasia. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Infigratinib for Achondroplasia in children by February 4, 2027, under an NDA from BridgeBio Pharma.
What the FDA is deciding on Infigratinib for Achondroplasia in children
The FDA is reviewing BridgeBio Pharma's application to approve Infigratinib for achondroplasia in children.
Once-daily oral pill under priority review for children with achondroplasia, the most common form of dwarfism; it would be an alternative to the 2 approved injections, daily Voxzogo and weekly Yuviwel. In the Phase 3 PROPEL 3 trial, infigratinib raised annualized height velocity by about 1.74cm per year over placebo in the main analysis, or 2.10cm per year as a simple average. It has Orphan Drug, Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations.
Who the Infigratinib decision matters to
Achondroplasia is the most common form of short-limbed dwarfism, caused by a mutation in the FGFR3 gene that disrupts the conversion of cartilage to bone in the growth plates. This results in disproportionate short stature with an average-size trunk but shortened arms and legs.
About 80% of cases arise from new spontaneous mutations rather than being inherited from an affected parent.
Prevalence: Approximately 1 in 25,000 live births; estimated 25,000 to 30,000 people in the United States. See our full Achondroplasia page for current treatments, recruiting trials, and community resources.
How Infigratinib works
Infigratinib: oral tyrosine kinase inhibitor of the FGFR1, FGFR2 and FGFR3 receptors that turns down the overactive FGFR3 signal behind achondroplasia. Our full Infigratinib profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of Infigratinib would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Achondroplasia treatment stands today
Read our full Achondroplasia treatment summary
Clinical trials for achondroplasia are exploring multiple strategies to promote bone growth and address the complications of FGFR3 overactivation. Voxzogo (vosoritide), a daily injection approved in November 2021, established the path for growth-promoting therapies, and in February 2026 the FDA approved Yuviwel (navepegritide), a once-weekly CNP injection for children 2 and older whose growth plates are still open.
Both received accelerated approval based on faster yearly growth, and continued approval of each depends on confirmatory trials. BridgeBio announced on October 6, 2026 that the FDA had accepted its application for infigratinib, a once-daily pill that blocks FGFR3, for children with achondroplasia, with a decision due February 4, 2027.
Other studies are recruiting, according to ClinicalTrials.gov in October 2026. BioMarin's ASPEN study compares its longer-acting CNP drug BMN 333 with Voxzogo in children 2 to 17 (NCT07441876).
Tyra Biosciences is testing TYRA-300, a drug that blocks FGFR3, in children 3 to 10 (NCT06842355), and BridgeBio and Ascendis are testing infigratinib and Yuviwel in babies and toddlers under 3 (NCT07169279, NCT06079398).
Trials measure treatment response through growth velocity, body proportions, and functional outcomes like mobility and respiratory function. For children, early enrollment in growth-promoting trials may maximize benefit while growth plates remain open.
Adults with achondroplasia may benefit from trials addressing spinal stenosis, sleep apnea, and pain management.
Your geneticist, orthopedic specialist, or skeletal dysplasia clinic can help evaluate whether current trials are appropriate. Little People of America and the MAGIC Foundation maintain information on clinical trials and connect families with specialized care centers.
The Achondroplasia page has every treatment and trial →Meanwhile, 11 Achondroplasia studies are recruiting or not yet recruiting
Whatever the FDA decides here, research on Achondroplasia does not stop. Of these, 6 test a treatment; the others follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Achondroplasia. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
When will the FDA decide on Infigratinib?
The FDA's target date (PDUFA date) for Infigratinib in Achondroplasia in children is February 4, 2027.
Who disclosed it: BridgeBio Pharma. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
What is Infigratinib being reviewed for?
BridgeBio Pharma submitted an NDA for Infigratinib in Achondroplasia in children.
What to know: Once-daily oral pill under priority review for children with achondroplasia, the most common form of dwarfism; it would be an alternative to the 2 approved injections, daily Voxzogo and weekly Yuviwel. In the Phase 3 PROPEL 3 trial, infigratinib raised annualized height velocity by about 1.74cm per year over placebo in the main analysis, or 2.10cm per year as a simple average. It has Orphan Drug, Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations.
How it works: Oral tyrosine kinase inhibitor of the FGFR1, FGFR2 and FGFR3 receptors that turns down the overactive FGFR3 signal behind achondroplasia.
More: the Infigratinib drug page explains it in plain language.
Is there already an FDA-approved treatment for Achondroplasia?
Yes. Trial Friend's drug list includes 2 FDA-approved drugs for Achondroplasia.
Approved: Voxzogo (vosoritide), Yuviwel (navepegritide).
Check: the Achondroplasia page also searches FDA drug labels for approved treatments.
What did the Infigratinib trials show?
PROPEL 3 (NCT06164951) was a Phase 3, double-blind trial in children aged 3 to 17 with open growth plates, who were randomized 2 to 1 to infigratinib or placebo for 52 weeks; 114 were randomized. The main measure, how fast children grew over a year (annualized height velocity), was 1.74cm a year higher on infigratinib than on placebo (95% confidence interval 1.31 to 2.17, P<0.001), and height z-score rose 0.32 more than on placebo.
More: the Infigratinib drug page has the full trial history and sources.
What are the side effects of Infigratinib?
Infigratinib has no US label for achondroplasia, so its side effects come from trials. In PROPEL 3, adverse events of any kind occurred in 71 of 74 children on infigratinib (96%) and 37 of 39 on placebo (95%).
More: the Infigratinib drug page has the safety details reported so far.
Can I get Infigratinib before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 11 Achondroplasia studies are recruiting or not yet recruiting, 6 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask BridgeBio Pharma directly. Registered programs are listed on ClinicalTrials.gov.
How much will Infigratinib cost?
BridgeBio Pharma has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Infigratinib decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from BridgeBio press release, Oct 6 2026. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.